Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.66 +0.01 (+0.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
From Pfizer Inc.
Via Business Wire
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
From Pfizer Inc.
Via Business Wire
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
From Pfizer Inc.
Via Business Wire
Pfizer Addresses Proposal for Metsera
From Pfizer Inc.
Via Business Wire
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via Investor Brand Network
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Nikki Barjon Ushers in a New Era of Branding and Legacy Building
Via Press Release Distribution Service
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
From Pfizer Inc.
Via Business Wire
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
From Pfizer Inc.
Via Business Wire
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
From Pfizer Inc.
Via Business Wire
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
From Pfizer Inc.
Via Business Wire
Pfizer Declares Fourth-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
From Pfizer Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
Via PRLog
Topics Artificial Intelligence
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
From Levin Papantonio
Via Business Wire
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
From Pfizer Inc.
Via Business Wire
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
From Arvinas Inc.
Via GlobeNewswire
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
University of the People – an accredited, tuition free University announces record-breaking enrollment for 2025
Unprecedented Student Growth including thousands of refugees 
Via PRUnderground
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
From Olema Oncology
Via GlobeNewswire
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market
Via AB Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.